Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NXTC - NextCure, Inc.

IEX Last Trade
0.89
-0.490   -55.056%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:16:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$1.38
-0.49
-35.51%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 3%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-10.52%
1 Month
-27.67%
3 Months
-36.64%
6 Months
-48.94%
1 Year
-24.52%
2 Year
-29.43%
Key data
Stock price
$0.89
P/E Ratio 
0.00
DAY RANGE
$0.91 - $1.38
EPS 
$0.00
52 WEEK RANGE
$0.94 - $2.57
52 WEEK CHANGE
-$23.86
MARKET CAP 
41.124 M
YIELD 
N/A
SHARES OUTSTANDING 
27.976 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.74
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$159,996
AVERAGE 30 VOLUME 
$215,141
Company detail
CEO: Michael S. Richman
Region: US
Website: nextcure.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

NextCure, Inc. engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. NC410, NC762, NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells.

Recent news